1. Introduction {#sec1}
===============

Transcatheter aortic valve replacement (TAVR) has revolutionized the current era of modern medicine by becoming the treatment of choice for patients with symptomatic severe aortic stenosis regardless of their surgical risk \[[@B1]\]. However, the high frequency of conduction disturbances, such as left bundle branch block (LBBB) and atrioventricular block, and the subsequent need for permanent pacemaker implantation (PPI) remain a challenge \[[@B2], [@B3]\]. Preexisting right bundle branch block (RBBB) has been established as a risk factor for PPI after TAVR \[[@B4], [@B5]\]. Preexisting RBBB in the general population and in patients with heart disease has been associated with increased risk of mortality \[[@B6]\]. However, data on the prognostic impact of preexisting RBBB on clinical outcomes after TAVR is limited. This systematic review and meta-analysis evaluates the impact of preexisting RBBB on clinical outcomes in patients undergoing TAVR.

2. Methods {#sec2}
==========

The main objective of this review was to assess if preexisting RBBB increased the risk of having PPI after TAVR. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement extension for network meta-analysis. The PRISMA flow diagram was used to depict the four phases of the review including identification, screening, eligibility, and inclusion. The PRISMA statement contains a checklist of 27 items required of systematic reviews and meta-analyses. The review was not registered a priori. No ethical approval was required since this meta-analysis uses only public published data.

2.1. Search Strategy {#sec2.1}
--------------------

We performed a systematic literature review to identify randomized and nonrandomized clinical studies that reported any clinical impact of patients undergoing TAVR with preexisting RBBB. Searches were limited to peer-reviewed primary research articles published in English, French, and Spanish up to May 17^th^, 2020. This research involved human subjects and described the clinical impact of RBBB on patients who underwent TAVR. We developed the search strategy according to available guidance from the Cochrane Collaboration.

The search strategy in MEDLINE explored Medical Subject Heading (MeSH) terms related to patients with TAVR and history of preexisting RBBB. The following search strategy was applied to search MEDLINE and we adapted it for the other databases: ("transcatheter aortic valve replacement"\[MeSH Terms\] OR ("transcatheter"\[All Fields\] AND "aortic"\[All Fields\] AND "valve"\[All Fields\] AND "replacement"\[All Fields\] AND "implantation"\[All Fields\])) OR "transcatheter aortic valve replacement"\[All Fields\]) AND ("bundle-branch block"\[MeSH Terms\] OR ("bundle-branch"\[All Fields\] AND "block"\[All Fields\]) OR "bundle-branch block"\[All Fields\] OR ("right"\[All Fields\] AND "bundle"\[All Fields\] AND "branch"\[All Fields\] AND "block"\[All Fields\]) OR "right bundle branch block"\[All Fields\]). The articles found to be relevant during the hand search were stored in EndNote. Selected articles underwent full evaluation to assess their potential inclusion in the systematic review.

2.2. Study Selection {#sec2.2}
--------------------

Articles were selected for inclusion based on predefined criteria, which included age, sex, TAVR, and preexisting RBBB, and the primary or secondary outcomes being mortality and clinical outcomes. Exclusion criteria were patients with LBBB and patients with normal sinus rhythm. We excluded case reports and studies with fewer than 10 subjects.

Two authors (GS, SL) independently read the trials and screened the abstracts to choose potentially relevant articles. Risk of bias in the studies was assessed at an individual level of each study. Selected articles underwent full evaluation to assess their potential inclusion in the systematic review.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Data were analyzed using Review Manager Software 5.3. We used fixed effects to assess the combined risk estimates according to I2 statistics. Analysis to determine sensitivity and publication bias was detected by funnel plots. *p* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

Our search yielded 224 abstracts. We excluded 199 studies at the abstract level and selected 24 full-text articles for detailed assessment; 14 studies were ultimately included in our systematic review and 11 studies were included in our meta-analysis. [Figure 1](#fig1){ref-type="fig"} describes the flowchart of included studies.

3.2. Baseline Characteristics of the Studies {#sec3.2}
--------------------------------------------

[Table 1](#tab1){ref-type="table"} shows the baseline characteristics of the included studies. All studies were published between 2010 and 2020. The 14 studies included 15,319 patients with 1,654 cases of preexisting RBBB. In nine of the included studies, preexisting RBBB was retrospectively identified as a risk factor for PPI. Therefore, baseline characteristics for patients with preexisting RBBB were not reported in these nine studies. For studies that did report characteristics for both RBBB and non-RBBB patients, the median age of the participants was 82.0 IQR (81.4--84.0). The median percentage of men was 49.1 IQR (39.2--58.4). For studies that reported these selected risk factors, the median percentage of hypertension was 76.1 IQR (74.8--81.9), the median percentage of diabetes was 30.2 IQR (28.9--32.8), the median BMI average was 26.7 IQR (24.3--27.1), the median percentage of coronary heart disease was 56.4 IQR (34.4--64.5), the median percentage of heart failure greater than or equal to New York Heart Association Class III was 74.7 IQR (47--77), and the median percentage of chronic obstructive pulmonary disease was 21.6 IQR (19.2--27.7). Current smoking percentage was 20.6% in the preexisting RBBB group and 19.9% in the no RBBB group for the one study that reported this risk factor. Racial characteristics were not reported by the included studies that used separate preexisting RBBB groups. Multiple centers were used by eight of the included studies and Europe, North America, South America, Japan, and Israel were the geographic regions represented.

3.3. PPI in Patients with Preexisting RBBB after TAVR {#sec3.3}
-----------------------------------------------------

Auffrett et al., Husser et al., van Gils et al., Tovia-Brodie et al., and Watanabe et al. reported various clinical outcomes in patients with preexisting RBBB after TAVR as summarized in [Table 2](#tab2){ref-type="table"} \[[@B7]--[@B11]\]. Auffrett et al. found patients with preexisting RBBB to have higher 30-day PPI rates (40.1% vs. 13.5%; *p* \< 0.001) \[[@B7]\]. Husser et al. reported a 30-day PPI rate of 39.2% in patients with preexisting RBBB after TAVR and found the ACURATE neo (Boston Scientific, Marlborough, Massachusetts) to have a lower rate of PPI when compared with the Edwards Sapien 3 (Edwards Lifesciences, Irvine, California) \[[@B8]\]. Van Gils et al. reported a 30-day PPI rate of 41.0% in patients with preexisting RBBB after TAVR and found the Boston Scientific Lotus (Boston Scientific, Marlborough, Massachusetts) to have the highest rate of PPI and the Edwards Sapien 3 and XT (Edwards Lifesciences, Irvine, California) to have the lowest rate of PPI \[[@B9]\]. Watanabe et al. found patients with preexisting RBBB to have higher 30-day rates of PPI (17.6% vs. 2.9%; *p* \< 0.01) \[[@B10]\]. Tovia-Brodie et al. did not report a 30-day PPI rate as they compared whether prophylactic PPI improved outcomes in patients with preexisting RBBB \[[@B11]\].

The nine remaining studies identified risk factors for 30-day PPI as summarized in [Table 2](#tab2){ref-type="table"} \[[@B12]--[@B20]\]. Meduri et al. identified preexisting RBBB, female sex, and depth of implantation to be a risk factors for 30-day PPI in their retrospective review of the REPRISE III (The Repositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus Valve System-Randomized Clinical Evaluation) trial \[[@B12]\]. Nazif et al. identified preexisting RBBB, prosthesis to left ventricular outflow tract diameter ratio, and left ventricular end-diastolic diameter as risk factors for 30-day PPI in their retrospective review of the PARTNER (Placement of AoRtic TraNscathetER Valves) trial \[[@B15]\]. Dhakal et al., Roten et al., Erkapic et al., Koos et al., and Fraccarro et al. all identified preexisting RBBB as a risk factor for PPI after TAVR in their retrospective single-center studies \[[@B13], [@B16]--[@B19]\]. Bagur et al. found preexisting RBBB as the only risk factor for PPI after TAVR in their comparison to surgical aortic valve replacement \[[@B14]\]. Guetta el al. identified preexisting RBBB and deep valve implantation as risk factors for PPI after TAVR in their retrospective review at three referral centers in Israel \[[@B20]\].

Meta-analysis of the included studies revealed a higher 30-day PPI rate of 38.1% in patients with preexisting RBBB when compared to a 30-day PPI rate of 11.4% in patients with no RBBB. This is a statistically significant increase in 30-day PPI rate in patients with preexisting RBBB with a risk ratio of 3.56 (95% CI 3.21--3.93, *p* \< 0.01). The forest plot for 30-day PPI rate is shown in [Figure 2](#fig2){ref-type="fig"}. Husser et al., Tovia-Brodie et al., and van Gils et al. results were not included in the 30-day PPI meta-analysis as these studies only included patients with preexisting RBBB and made no comparisons to patients without RBBB. In the two included studies that reported 30-day mortality as an outcome, meta-analysis revealed a higher 30-day mortality rate of 9.5% in patients with preexisting RBBB compared to a 30-day mortality rate of 6.3% in patients with no RBBB. This is a statistically significant increase in 30-day mortality in patients with preexisting RBBB with a risk ratio of 1.60 (95% CI 1.14--2.25, *p* \< 0.01). The forest plot for 30-day morality rate is shown in [Figure 3](#fig3){ref-type="fig"}.

4. Discussion {#sec4}
=============

This is the first systematic review and meta-analysis to demonstrate the impact of preexisting RBBB on new pacemaker implantation after TAVR. Our findings are derived from 14 studies reporting clinical outcomes in a total of 1,654 patients with preexisting RBBB after TAVR. The incidence of new PPI was significantly increased in patients with preexisting RBBB after TAVR. Increased all-cause and cardiovascular mortality has been demonstrated in patients with preexisting RBBB after TAVR.

The prognostic value of RBBB has shown mixed results in previous studies with healthy participants and with patients with heart disease \[[@B21]--[@B28]\]. Bussink et al. found RBBB to be associated with increased all-cause and cardiovascular mortality in both men and women from the general population \[[@B21]\]. Abdel-Qadir et al. found no prognostic value of RBBB in patients hospitalized with heart failure; however, Barshehet et al. found RBBB to be associated with increased long-term mortality risk in hospitalized patients with systolic heart failure \[[@B22], [@B23]\]. Melgaregjo-Moreno et al. found new permanent RBBB to be associated with increased 30-day and seven-year mortality in patients with acute myocardial infarction \[[@B24]\]. Wong et al. found RBBB accompanying anterior acute myocardial infarction to be associated with increased 30-day mortality \[[@B28]\]. Long-term epidemiological studies in men from the general population have found a higher incidence of RBBB with aging, hypertension, and diabetes mellitus \[[@B25], [@B26]\]. Zhang et al. found RBBB in women with cardiovascular disease to be associated with an increased risk of coronary heart disease death over 14 years of follow-up. However, RBBB in women free of cardiovascular disease was not associated with increased mortality \[[@B27]\]. Meta-analysis completed by Xiong et al. found RBBB to be associated with an increased risk of mortality in the general population and in patients with heart disease \[[@B6]\]. The exact mechanism by which RBBB increases mortality has not been elucidated, although underlying conduction system disease can predispose patients to various arrhythmias. The association of RBBB with decreased left ventricular ejection fraction in patients with prior myocardial infarction or heart failure may provide a clue towards the underlying mechanism \[[@B23], [@B28]\]. The various comorbidities and underlying heart disease in patients with RBBB may also explain the increased mortality.

A previous meta-analysis by Siontis et al. demonstrated the significance of RBBB in the requirement for PPI after TAVR. Male sex, first-degree AV block, left anterior hemiblock, and intraprocedural AV block were also found to be predictive of PPI after TAVR \[[@B4]\]. The newer studies highlighted in this meta-analysis emerged to specifically focus on the clinical impact of preexisting RBBB after TAVR, which is important for improving patient outcomes \[[@B7]--[@B10]\].

In TAVR, conduction disturbances are a common complication likely due to direct insult to the left bundle branch because of the anatomical relationship between the aortic annulus and the conduction system \[[@B29]\]. New-onset LBBB develops in 5% to 65% of patients undergoing TAVR, and its persistence can result in PPI in 15% to 20% of cases \[[@B29]\]. New-onset LBBB after TAVR has been associated with increased risk of cardiac death and PPI at one year follow-up \[[@B30]\]. Preexisting RBBB with new-onset LBBB after TAVR will usually generate PPI during the index hospitalization. Chorianopoulos et al. demonstrated that postprocedural bradyarrhythmias develop in 36.2% of patients after TAVR with 3.8% remaining \>96 hours after TAVR. Preexisting RBBB was found to be the only predictor of postprocedural bradyarrhythmias \[[@B5]\]. Late-onset new LBBB \>3 months after TAVR is a rare complication seen in only 0.8% of patients \[[@B31]\]. Development of high degree AV block is a common complication seen in up to 58.8% of patients with preexisting BBB or BBB occurring during TAVR \[[@B32]\]. These late conduction disorders in patients with preexisting RBBB can lead to cardiac complications such as heart failure and sudden cardiac death.

This systematic review and meta-analysis reveals increased PPI, all-cause mortality, and cardiac mortality in patients with preexisting RBBB after TAVR. This is clinically significant given the recent trend towards early discharge after TAVR \[[@B33]\]. Patients with preexisting RBBB may need additional monitoring after TAVR to detect conduction disturbances and ensure safe discharge. Early electrocardiographic monitoring may be beneficial as part of the TAVR work-up as Urena et al. found that newly diagnosed preprocedural arrhythmias are common and associated with higher rates of PPI after the procedure \[[@B34]\]. Additional strategies for managing preexisting RBBB in patients undergoing TAVR may emerge as we understand more about conduction disturbances following TAVR.

Preexisting RBBB is a common underlying conduction disturbance in patients undergoing TAVR and is associated with increased risk of PPI at 30 days and all-cause and cardiovascular mortality. Future studies will be needed to evaluate optimal management of patients with preexisting RBBB undergoing TAVR. Larger prospective studies are needed to investigate the optimal timing for PPI after TAVR and to evaluate prophylactic PPI in patients with preexisting RBBB prior to TAVR. Larger prospective studies are needed to investigate strategies for early detection of conduction disturbances in patients with preexisting RBBB. Until more data is available, there are many multicenter and literature-based decisional algorithms to guide PPI decision-making \[[@B35]\]. Careful monitoring to detect arrhythmias after TAVR may be necessary to improve clinical outcomes in patients with preexisting RBBB.

5. Limitations {#sec5}
==============

The limitations for this systematic review and meta-analysis are influenced by the limitations of the included studies. Auffrett et al. used a nonrandomized study design that may lead to confounders influencing the relationship between preexisting RBBB and outcomes \[[@B7]\]. The studies by Husser et al. and van Gils et al. are limited by their observational design \[[@B8], [@B9]\]. Tovia-Brodie et al. used a single-center retrospective design and did not use randomization to determine prophylactic pacemaker implantation \[[@B11]\]. The results from Watanabe et al. are limited by the relatively small size of the cohort (*n* = 749) and the relatively short median follow-up of 16 months \[[@B10]\]. The retrospective studies of existing data are subject to all of the limitations inherent to this study design \[[@B12]--[@B20]\]. Availability of specific data points, such as medication that could influence cardiac conduction, is a common limitation for retrospective studies. Roten et al., Erkapic et al., Koos et al., Fraccaro et al., and Guetta et al. all had small sample sizes of less than 100 patients in their studies \[[@B16]--[@B20]\]. All of the included studies are likely influenced by between-center variability and the lack of centralized independent assessment of procedural results and outcomes. The various valve types used in each study likely influence the generalizability of the aggregate data as specific valve types have shown different rates of procedural complications.

6. Conclusion {#sec6}
=============

Conduction issues after TAVR continue to remain a common complication during the management of severe aortic stenosis. This current systematic review and meta-analysis indicates that patients with preexisting RBBB have a higher incidence of PPI and all-cause mortality after 30 days after TAVR compared with patients without RBBB. Further trials are needed to compare the clinical outcomes based on TAVR valve types and assess the benefit of PPI in patients with RBBB after TAVR. In addition, understanding the progression and prevention of electrical conduction disease are necessary for appropriate risk stratification, interventional strategy, and avoidance of pacemaker implantation.
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###### 

Baseline characteristics of the included studies.

  Study author, year          Region                           Sample size         RBBB status   Number of patients   Mean age (years)    Men (%)   HTN (%)             Smoking (%)   DM (%)   BMI (kg/m^2^)       CHD (%)   NYHA \> III (%)   COPD (%)
  --------------------------- -------------------------------- ------------------- ------------- -------------------- ------------------- --------- ------------------- ------------- -------- ------------------- --------- ----------------- ----------
  Watanabe et al., 2016       Japan                            749                 RBBB          102                  85.0 (81.0--89.0)   39.2      80.4                20.6          26.4     22.2 (19.5--24.9)   28.0      52                21.6
  No RBBB                     647                              85.0 (82.0--88.0)   32.9          74.8                 19.9                25.0      21.7 (19.3--24.1)   24.2          47       20.2                                            
  van Gils et al., 2017       Europe                           2,845               RBBB          306                  83 ± 7              63        NR                  NR            30       27 ± 5              NR        77                30
                                                                                                                                                                                                                                               
  Auffrett et al., 2017       Europe, Canada, S. America       3,527               RBBB          362                  81.7 ± 7.3          58.4      74.7                NR            28.9     27.2 ± 5.2          59.2      74.7              29.9
  No RBBB                     3165                             81.4 ± 7.6          49.1          77.2                 NR                  30.2      26.7 ± 5.1          53.5          74.7     25.5                                            
                                                                                                                                                                                                                                               
  Husser et al., 2019         Germany and Switzerland          4,305               RBBB -S3      198                  82.0 (78.0--85.0)   27.8      86.4                NR            32.8     26.4 (23.7--29.8)   68.2      78.3              18.2
  RBBB -NEO                   98                               81.0 (78.0--84.0)   39.8          92.9                 NR                  32.7      27.9 (24.7--31.0)   66.3          79.6     14.3                                            
                                                                                                                                                                                                                                               
  Tovia-Brodie et al., 2020   Israel                           90                  RBBB          50                   81 ± 8              58        70                  NR            34       NR                  NR        18                NR
  RBBB -PM                    40                               84 ± 6              75            75                   NR                  43        NR                  NR            20       NR                                              
                                                                                                                                                                                                                                               
  Meduri et al., 2019         N. America, Europe, Australia    912                 RBBB          85                   NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     827                              NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              
                                                                                                                                                                                                                                               
  Dhakal et al. 2020          Arizona, USA                     176                 RBBB          36                   NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     140                              NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              
                                                                                                                                                                                                                                               
  Bagur et al. 2012           Canada                           411                 RBBB          20                   NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     391                              NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              
                                                                                                                                                                                                                                               
  Nazif et al. 2015           United States, Canada, Germany   1,973               RBBB          312                  NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     1661                             NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              
                                                                                                                                                                                                                                               
  Roten et al. 2010           Switzerland                      67                  RBBB          13                   NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     54                               NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              
                                                                                                                                                                                                                                               
  Erkapic et al. 2010         Germany                          50                  RBBB          7                    NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     43                               NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              
                                                                                                                                                                                                                                               
  Koos et al. 2011            Germany                          80                  RBBB          6                    NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     74                               NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              
                                                                                                                                                                                                                                               
  Fraccaro et al. 2011        Italy                            64                  RBBB          8                    NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     56                               NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              
                                                                                                                                                                                                                                               
  Guetta et al. 2011          Israel                           70                  RBBB          11                   NR                  NR        NR                  NR            NR       NR                  NR        NR                NR
  No RBBB                     59                               NR                  NR            NR                   NR                  NR        NR                  NR            NR       NR                                              

Values are mean ± SD, median (interquartile range), or *n* (%). NR: not reported; HTN: hypertension; DM: diabetes mellitus; CHD: coronary heart disease; RBBB: right bundle branch block; BMI: body mass index; NYHA: New York Heart Association; COPD: chronic obstructive lung disease.

###### 

Outcomes of patients with preexisting RBBB after TAVR summary table.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References            Year   Region                           Centers        Patients w/RBBB   Valves                                                Primary outcome                           Other outcomes
  --------------------- ------ -------------------------------- -------------- ----------------- ----------------------------------------------------- ----------------------------------------- -------------------------------------------------------------
  Watanabe et al.       2016   Japan                            8              102               ES-XT                                                 Various clinical outcomes                 PPI, mortality, bleeding, etc.

                                                                                                                                                                                                 

                                                                                                                                                                                                 

  van Gils et al.       2017   Europe                           4              306               CoreValve\                                            PPI within 30 days                        New onset conduction disturbances
                                                                                                 ES-XT\                                                                                          
                                                                                                 ES-3\                                                                                           
                                                                                                 Lotus                                                                                           

                                                                                                                                                                                                 

  Auffrett et al.       2017   Europe, Canada, S. America       Not reported   362               Not reported                                          All-cause mortality                       CV death, SCD, PPI

                                                                                                                                                                                                 

  Husser et al.         2019   Germany and Switzerland          7              296               Neo\                                                  PPI within 30 days                        Device failure
                                                                                                 ES-3                                                                                            

                                                                                                                                                                                                 

  Tovia-Brodie et al.   2020   Israel                           1              90                CoreValve\                                            Outcomes comparison for prophylactic PM   Predictors for pacing
                                                                                                 ES-3\                                                                                           
                                                                                                 ES-XT\                                                                                          
                                                                                                 Evolute R\                                                                                      
                                                                                                 Lotus                                                                                           

                                                                                                                                                                                                 

  Meduri et al.         2019   N. America, Europe, Australia    55             85                CoreValve\                                            PPI within 30 days                        Predictors for pacing, mortality, stroke, rehospitalization
                                                                                                 Lotus                                                                                           

                                                                                                                                                                                                 

  Dhakal et al.         2020   Arizona, USA                     1              36                Not reported, balloon expandable and self-expanding   PPI within 30 days                        Predictors for pacing

                                                                                                                                                                                                 

  Bagur et al.          2012   Canada                           3              20                CE\                                                   PPI within 30 days                        Predictors for pacing
                                                                                                 ES\                                                                                             
                                                                                                 ES-XT                                                                                           

                                                                                                                                                                                                 

  Naziif et al.         2015   United States, Canada, Germany   21             312               ES                                                    PPI within 30 days                        Predictors for pacing

                                                                                                                                                                                                 

  Roten et al.          2010   Switzerland                      1              13                CoreValve                                             PPI within 30 days                        Predictors for pacing

  ES                                                                                                                                                                                             

                                                                                                                                                                                                 

  Erkapic et al.        2010   Germany                          1              7                 CoreValve                                             PPI within 30 days                        Predictors for pacing

  ES                                                                                                                                                                                             

                                                                                                                                                                                                 

  Koos et al.           2011   Germany                          1              6                 CoreValve                                             PPI within 30 days                        Predictors for pacing

  ES                                                                                                                                                                                             

                                                                                                                                                                                                 

  Fraccaro et al.       2011   Italy                            1              8                 CoreValve                                             PPI within 30 days                        Predictors for pacing

                                                                                                                                                                                                 

  Guetta et al.         2011   Israel                           3              11                CoreValve                                             PPI within 30 days                        Predictors for pacing
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PPI: permanent pacemaker implantation; SCD: sudden cardiac death; CV: cardiovascular; ES-XT: Edwards SAPIEN XT; ES-3: Edwards SAPIEN 3; ES: Edwards SAPIEN; CE: Cribier-Edwards.
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